Fmoc-哌嗪盐酸盐

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 中文名称: Fmoc-哌嗪盐酸盐
• 中文别名: FMOC-哌嗪盐酸盐
• 英文名称: (9H-fluoren-9-yl)methyl piperazine-1-carboxylate hydrochloride
• 英文别名: N-(9-fluorenylmethoxycarbonyl)piperazine hydrochloride；Fmoc-piperazine hydrochloride；Fmoc-PIP.HCl；9H-fluoren-9-ylmethyl piperazin-4-ium-1-carboxylate;chloride
• 化学式: C₁₉H₂₀N₂O₂*ClH
• 分子量: 344.841
• InChiKey: IXWMXZSFRQQDDO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.26
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  41.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  Fmoc-哌嗪盐酸盐 在 palladium on activated charcoal 水 、 氢气 、 1-羟基苯并三唑 、 溶剂黄146 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 0.83h， 生成 4-[(S)-3-tert-butoxycarbonylamino-6-dimethylamino-hexanoyl]piperazine-1-carboxylic acid 9H-fluoren-9-ylmethyl ester
  参考文献：
  名称：

  Design and Synthesis of Novel Sulfonamide-Containing Bradykinin hB₂ Receptor Antagonists. 2. Synthesis and Structure−Activity Relationships of α,α-Cycloalkylglycine Sulfonamides

  摘要：

  Recently we reported on the design and synthesis of a novel class of selective nonpeptide bradykinin (BK) B-2 receptor antagonists (J. Med. Chem. 2006, 3602-3613). This work led to the discovery of MEN 15442, an antagonist with subnanomolar affinity for the human B2 receptor (hB2R), which also displayed significant and prolonged activity in vivo (for up to 210 min) against BK-induced bronchoconstriction in the guinea-pig at a dose of 300 nmol/kg (it), while demonstrating only a slight effect on BK-induced hypotension. Here we describe the further optimization of this series of compounds aimed at maximizing the effect on bronchoconstriction and minimizing the effect on hypotension, with a view to developing topically delivered drugs for airway diseases. The work led to the discovery of MEN 16132, a compound which, after intratracheal or aerosol administration, inhibited, in a dose-dependent manner, BK-induced bronchoconstricton in the airways, while showing minimal systemic activity. This compound was selected as a preclinical candidate for the topical treatment of airway diseases involving kinin B2 receptor stimulation.

  DOI：

  10.1021/jm061143k

文献信息

• [EN] OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE<br/>[FR] LIGANDS DE LIAISON À L'OPSINE, COMPOSITIONS ET PROCÉDÉS D'UTILISATION
  申请人：BIKAM PHARMACEUTICALS INC

  公开号：WO2010147653A1

  公开（公告）日：2010-12-23

  Compounds and compositions of said compounds along with methods of use of compounds are disclosed for treating ophthalmic conditions related to mislocalization of opsin proteins, the misfolding of mutant opsin proteins and the production of toxic visual cycle products that accumulate in the eye. Compounds and compositions useful in the these methods, either alone or in combination with other therapeutic agents, are also described.

  本文披露了用于治疗与视蛋白蛋白质错位、突变视蛋白蛋白质的错误折叠以及在眼睛中积累的有毒视觉循环产物有关的眼科疾病的化合物及该化合物的组合物，以及使用该化合物的方法。还描述了在这些方法中有用的化合物和组合物，无论是单独使用还是与其他治疗剂联合使用。
• Piperazine derivatives for treatment of bacterial infections
  申请人：——

  公开号：US20040077655A1

  公开（公告）日：2004-04-22

  Piperazine derivatives and pharmaceutically acceptable derivatives thereof useful in methods of treatment of bacterial infections in mammals, particularly in man.

  哌嗪衍生物及其药用可接受衍生物在哺乳动物，特别是人类的细菌感染治疗方法中有用。
• [EN] INHIBITORS OF LEUKOTRIENE PRODUCTION<br/>[FR] INHIBITEURS DE LA PRODUCTION DE LEUCOTRIÈNE
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2015009611A1

  公开（公告）日：2015-01-22

  The present invention relates to aryl pyrazoles, and pharmaceutically acceptable salts thereof. The aryl pyrazoles of the present invention are useful as inhibitors of leukotriene A4 hydrolase (LTA4H) and treating LTA4H related disorders. The present invention also relates to pharmaceutical compositions comprising the aryl pyrazoles of the present invention, methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.

  本发明涉及芳基吡唑及其药用可接受盐。本发明的芳基吡唑可用作白三烯A4水解酶（LTA4H）的抑制剂，并用于治疗与LTA4H相关的疾病。本发明还涉及包含本发明的芳基吡唑的药物组合物，使用这些化合物治疗各种疾病和疾病的方法，以及制备这些化合物的方法。
• Novel compounds
  申请人：——

  公开号：US20040102633A1

  公开（公告）日：2004-05-27

  Certain compounds of formula (I) below or a pharmaceutically acceptable salt or hydrate thereof: wherein: R 1 is H or alkyl; R 2 is —R 8 R 9 ; R 8 is a single bond or alkyl, optionally substituted one or more times by hydroxy; R 9 is aryl or cycloalkyl or heteroaryl, optionally substituted one or more times by hydroxy, alkoxy, or alkoxyalkyl; R 3 is H or alkyl or cycloalkyl or cycloalkylalkyl, optionally substituted one or more times by hydroxy or by one or more fluorines; R 4 is —NR 10 R 11 ; R 10 and R 11 are independently selected from H or alkyl, or R 10 and R 11 together with the nitrogen atom to which they are attached form a saturated or unsaturated heterocyclic ring comprising 3-8 ring members, which heterocyclic ring is unsubstituted or is substituted one or more times by one or more substituents R 12 ; R 12 is oxo or —R 13 R 14 R 15 , wherein R 13 is a single bond or alkyl, R 14 is OC(O) or C(O)O, and R 15 is H or alkyl; R 5 is an alkyl, cycloalkyl, cycloalkylalkyl, aryl, or single or fused ring aromatic heterocyclic group, which group is unsubstituted or is substituted one or more times by one or more substituents selected from halo such as fluoro, alkyl or haloalkyl such as fluoroalkyl; R 6 represents H or up to three substituents independently selected from the list consisting of: alkyl, alkenyl, aryl, alkoxy or a hydroxylated derivative thereof, hydroxy, halogen, nitro, cyano, carboxy, carboxamido, sulphonamido, alkoxycarbonyl, haloalkyl such as trifluoromethyl, acyloxy, amino, mono- or di-alkylamino, alkoxyamido, alkoxycarboxylate or an esterified derivative thereof; R 7 is H or halo; a is 1-6; and any of R 1 , R 3 , R 5 , R 8 , R 9 , R 10 , R 11 and R 12 may optionally be substituted one or more times by halo, hydroxy, amino, cyano, nitro, carboxy or oxo; a process for preparing such compounds, a pharmaceutical composition comprising such compounds and the use of such compounds and composition in medicine.

  以下式（I）的某些化合物或其药学上可接受的盐或水合物： 其中： R1为H或烷基； R2为—R8R9； R8为单键或烷基，可以被羟基替代一次或多次； R9为芳基或环烷基或杂环烷基，可以被羟基、烷氧基或烷氧基烷基替代一次或多次； R3为H或烷基或环烷基或环烷基烷基，可以被羟基或一次或多次氟原子替代； R4为—NR10R11； R10和R11独立选择自H或烷基，或者R10和R11连同它们连接的氮原子形成一个由3-8个环成员组成的饱和或不饱和杂环，该杂环未被取代或被一个或多个取代基R12取代一次或多次； R12为氧代或—R13R14R15，其中R13为单键或烷基，R14为OC（O）或C（O）O，R15为H或烷基； R5为烷基、环烷基、环烷基烷基、芳基或单环或融合环芳基杂环基，该基未被取代或被一个或多个取代基选自卤素如氟、烷基或卤代烷基如氟代烷基取代一次或多次； R6代表H或最多三个独立选择自以下列表中的取代基：烷基、烯烃基、芳基、烷氧基或其羟基衍生物、羟基、卤素、硝基、氰基、羧基、羧胺基、磺胺基、烷氧羰基、卤代烷基如三氟甲基、酰氧基、氨基、单烷基或二烷基氨基、烷氧胺基、烷氧羧酸酯或其酯化衍生物； R7为H或卤素； a为1-6； 以及R1、R3、R5、R8、R9、R10、R11和R12中的任何一个可以选择性地被卤素、羟基、氨基、氰基、硝基、羧基或氧代基取代一次或多次； 制备这种化合物的过程，包括这种化合物的药物组合物以及这种化合物和组合物在医学中的应用。
• [EN] ANTIBACTERIAL AGENTS<br/>[FR] AGENTS ANTIBACTERIENS
  申请人：BRITISH BIOTECH PHARM

  公开号：WO2004033441A1

  公开（公告）日：2004-04-22

  Compounds of formula (II) have antibacterial activity: wherein: Q represents a radical of formula -N(OH)CH(=0) or formula -C(=O)NH(OH); R1 represents hydrogen, methyl or trifluoromethyl or, except when Q is a radical of formula -N(OH)CH(=0), a hydroxy, halo or amino group; R2 represents a group R10-(D)n-(ALK)m- wherein R10 represents hydrogen or an optionally substituted C1-C6 alkyl, C2-C6 alkynyl, C2-C6 alkynyl, cycloalkyl, aryl, or heterocyclyl group and ALK represents a straight or branched divalent C1-C6 alkylene, C2-C6 alkynylene, or C2-C6 alkynylene radical, and may be interrupted by one or more non-adjacent -NH-, -O- or -S­linkages, D represents -NH-, -O- or -S-, and m and n are independently 0 or 1; R4 represents the side chain of a natural or non-natural alpha amino acid; ring A represents an optionally substituted monocyclic heterocyclic ring containing from 5 to 7 ring atoms, one of which is the nitrogen atom shown, the remaining ring atoms being selected from compatible combinations of carbon, oxygen, sulfur and nitrogen; X is oxygen or sulfur; Y is oxygen, sulfur or -NH-; R is 0, 1, 2 or 3; and ring B represents an optionally substituted carbocyclic or heterocyclic ring system.

  式（II）的化合物具有抗菌活性：其中：Q代表式-N（OH）CH（=0）或式-C（=O）NH（OH）的基团；R1代表氢，甲基或三氟甲基或者除非Q是式-N（OH）CH（=0）的基团，还可以是一个羟基，卤素或氨基；R2代表一个基团R10-(D)n-(ALK)m-，其中R10代表氢或者一个可选择取代的C1-C6烷基，C2-C6炔基，C2-C6炔基，环烷基，芳基或杂环烷基，ALK代表一条直链或支链的二价C1-C6烷基，C2-C6炔基或C2-C6炔基基团，并且可以被一个或多个非相邻的-NH-，-O-或-S-连接所中断，D代表-NH-，-O-或-S-，m和n独立地为0或1；R4代表天然或非天然α-氨基酸的侧链；环A代表一个可选择取代的含有5到7个环原子的单环杂环，其中之一是所示的氮原子，其余环原子选自碳，氧，硫和氮的兼容组合；X是氧或硫；Y是氧，硫或-NH-；R为0，1，2或3；环B代表一个可选择取代的碳环或杂环环系统。